Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

@article{Guigon2010InhibitionOM,
  title={Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.},
  author={C{\'e}line J. Guigon and Laura Fozzatti and Changxue Lu and Mark C. Willingham and Sheue-yann Cheng},
  journal={Carcinogenesis},
  year={2010},
  volume={31 7},
  pages={1284-91}
}
Selective drugs targeting dysregulated oncogenic pathways are promising cancer therapies. Because the mammalian target of rapamycin complex 1 (mTORC1) pathway is hyperactivated in human follicular thyroid cancer (FTC), we hypothesized that its inhibition could block cancer development and progression. We, therefore, analyzed the effect of a treatment with a specific mTORC1 inhibitor (RAD001) in a faithful mouse model of FTC with constitutive mTORC1 activation (TRbeta(PV/PV)Pten(+/-) mice). The… CONTINUE READING